人类对抗癌症的历程漫长而艰辛。认知局限曾使古人视其为神秘的“神罚”，无从应对。近代，手术与化疗等传统手段的出现，首次为患者带来了生存的曙光，标志着人类开始主动反击。如今，靶向治疗与免疫疗法的崛起更创造了医学奇迹——部分癌症如淋巴瘤、睾丸癌的治愈率已突破90%。随着技术迭代与监管完善，基因编辑技术正成为实现癌症“根治”梦想的核心引擎。

在这场攻坚战中，一项名为“合成致死”（Synthetic Lethality, SL）的效应提供了独特的“基因剪刀”策略。科学家最初在果蝇中发现^[1]：当两个特定基因同时失效时，细胞会死亡；但如果其中任意一个单独失效，细胞却能存活。这揭示了关键原理：携带特定致癌突变的癌细胞，高度依赖另一个“补偿性”基因维持生存。精准找到这些“合成致死伙伴”基因，就能设计靶向药物，摧毁癌细胞的同时保护健康组织。

这一理论已在临床绽放光芒。以卵巢癌为例，BRCA1突变的癌细胞极度依赖PARP蛋白修复DNA损伤。PARP抑制剂（如奥拉帕利）正是据此设计：阻断PARP，导致癌细胞DNA损伤累积无法修复而死亡。这类药物显著延长了患者无进展生存期^{[2, 3]}，成为合成致死理论成功应用的典范，验证了其巨大潜力。

然而，如何在浩瀚的基因组海洋中高效、系统地挖掘更多有价值的“合成致死伙伴”靶点？CRISPR基因编辑文库筛选技术提供了“金标准”方案。其高通量特性使得一次实验就能覆盖数万基因，通过分析药物处理前后sgRNA的丰度变化，快速锁定对癌细胞生存至关重要的关键基因。这如同在基因迷宫中精准导航，大大加速了新靶点的发现。而海星生物的文库筛选服务，正是这一技术从实验室走向临床转化的关键桥梁。

领先技术

海星生物汇聚了资深基因编辑专家与生物信息分析师团队，平均拥有8年以上丰富经验。我们运用前沿AI算法精准预测sgRNA特异性得分，显著降低脱靶风险（如全基因组文库脱靶率<0.5%）；并通过深度数据挖掘算法，为客户提供高价值的精准分析报告。

严格质控

实验室通过ISO9001认证，建立了完善的质量管理体系。文库质粒采用低内毒转染级标准制备，确保纯度和活性；病毒颗粒提供详实滴度报告；文库细胞保证高覆盖度与均一性，为实验的可重复性与可靠性奠定坚实基础。

高度定制

我们深刻理解不同研究目标的独特性。无论您是基础科研机构探索新型致癌机制，还是药企进行药物靶点发现与研发，海星生物都能提供端到端的个性化服务。

全基因组文库：覆盖人/鼠2万基因，包含7w+条经严格验证的高特异性sgRNA（每个基因3条）。

亚基因组文库：提供靶向药物靶点、激酶、膜蛋白、干扰素刺激基因等的成品敲除/激活/干扰文库。

深度定制文库：可针对特定癌种（如肝癌、结直肠癌）或关键通路（如PI3K-AKT、DNA损伤修复）构建专属文库。

选择海星生物，就是选择更专业、更高效的基因编辑技术支持，为您的癌症研究项目注入强大动力，助力在攻克癌症的道路上迈出坚实步伐。立即联系海星生物，让我们携手开启 CRISPR 文库筛选的创新之旅，共同探索癌症治疗的无限可能 ！

参考文献

[1]BRIDGES C, BREHME K S. The mutants of drosophila melanogaster, F 1944, 1944 [C].

[2]FäRKKILä A, GULHAN D C, CASADO J, et al. Immunogenomic profiling determines responses to combined PARP and PD-1 inhibition in ovarian cancer [J]. Nat Commun, 2020, 11(1): 1459.

[3]PUJADE-LAURAINE E, SELLE F, SCAMBIA G, et al. Maintenance olaparib rechallenge in patients with platinum-sensitive relapsed ovarian cancer previously treated with a PARP inhibitor (OReO/ENGOT-ov38): a phase IIIb trial [J]. Ann Oncol, 2023, 34(12): 1152-64.

[4]FARMER H, MCCABE N, LORD C J, et al. Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy [J]. Nature, 2005, 434: 917–21.

[5]JIA X, ZHU X, CHEN S, et al. Comprehensive multi-omics analyses expose a precision therapy strategy that targets replication stress in hepatocellular carcinoma using WEE1 inhibition [J]. Journal of Advanced Research, 2025.

[6]TIEN J C-Y, LUO J, CHANG Y, et al. CDK12 loss drives prostate cancer progression, transcription-replication conflicts, and synthetic lethality with paralog CDK13 [J]. CR Med, 2024, 5(10).

[7]CHEN W, YANG K-B, ZHANG Y-Z, et al. Synthetic lethality of combined ULK1 defection and p53 restoration induce pyroptosis by directly upregulating GSDME transcription and cleavage activation through ROS/NLRP3 signaling [J]. J Exp Clin Cancer Res, 2024, 43(1): 248.

[8]KYRKOU A, VALLA R, ZHANG Y, et al. G6PD and ACSL3 are synthetic lethal partners of NF2 in Schwann cells [J]. Nat Commun, 2024, 15(1): 5115.

[9]FENG X, TANG M, DEDE M, et al. Genome-wide CRISPR screens using isogenic cells reveal vulnerabilities conferred by loss of tumor suppressors [J]. Science Advances, 2022, 8(19): eabm6638.

[10]LIN J-F, HU P-S, WANG Y-Y, et al. Phosphorylated NFS1 weakens oxaliplatin-based chemosensitivity of colorectal cancer by preventing PANoptosis [J]. Signal Transduct Target Ther, 2022, 7: 54.

[11]GALLO D, YOUNG J T F, FOURTOUNIS J, et al. CCNE1 amplification is synthetic lethal with PKMYT1 kinase inhibition [J]. Nature, 2022, 604(7907): 749-56.

[12]OLIVIERI M, CHO T, ÁLVAREZ-QUILóN A, et al. A Genetic Map of the Response to DNA Damage in Human Cells [J]. Cell, 2020, 182(2): 481-96.e21.

[13]SHEFFER M, LOWRY E, BEELEN N, et al. Genome-scale screens identify factors regulating tumor cell responses to natural killer cells [J]. Nat Genet, 2021, 53(8): 1196-206.

[14]HUNDLEY F V, SANVISENS DELGADO N, MARIN H C, et al. A comprehensive phenotypic CRISPR-Cas9 screen of the ubiquitin pathway uncovers roles of ubiquitin ligases in mitosis [J]. Mol Cell, 2021, 81(6): 1319-36.e9.

[15] VICHAS A, RILEY A K, NKINSI N T, et al. Integrative oncogene-dependency mapping identifies RIT1 vulnerabilities and synergies in lung cancer [J]. Nat Commun, 2021, 12(1): 4789.

[16]PICCO G, CATTANEO C M, VAN VLIET E J, et al. Werner Helicase Is a Synthetic-Lethal Vulnerability in Mismatch Repair–Deficient Colorectal Cancer Refractory to Targeted Therapies, Chemotherapy, and Immunotherapy [J]. Cancer Discovery, 2021, 11(8): 1923-37.

[17]HOSHINO A, WANG W J, WADA S, et al. The ATP/ADP translocase drives mitophagy independent of nucleotide exchange [J]. Nature, 2019, 575(7782): 375-9.

[18]VERVOORT S J, WELSH S A, DEVLIN J R, et al. The PP2A-Integrator-CDK9 axis fine-tunes transcription and can be targeted therapeutically in cancer [J]. Cell, 2021, 184(12): 3143-62.e32.

[19]TUNG N M, ROBSON M E, VENTZ S, et al. TBCRC 048: Phase II Study of Olaparib for Metastatic Breast Cancer and Mutations in Homologous Recombination-Related Genes [J]. JCO, 2020, 38(36): 4274-82.

[20]LIU X, LIU T, SHANG Y, et al. ERCC6L2 promotes DNA orientation-specific recombination in mammalian cells [J]. Cell Res, 2020, 30(9): 732-44.

[21]BENSLIMANE Y, BERTOMEU T, COULOMBE-HUNTINGTON J, et al. Genome-Wide Screens Reveal that Resveratrol Induces Replicative Stress in Human Cells [J]. Mol Cell, 2020, 79(5): 846-56.e8.

[22]LIANG J, ZHAO H, DIPLAS B H, et al. Genome-Wide CRISPR-Cas9 Screen Reveals Selective Vulnerability of ATRX-Mutant Cancers to WEE1 Inhibition [J]. Cancer Research, 2020, 80(3): 510-23.